Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.
News|Articles|September 30, 2026
Q4 2026 Preview: 7 FDA Decisions to Watch
Author(s)Abigail Brooks, MA
Fact checked by: Victoria Johnson
Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.
Advertisement
Advertisement
Q4 opens with a concentrated slate of regulatory decisions spanning hepatology, nephrology, cardiovascular disease, endocrinology, and dermatology. October begins with what could be a first-in-class hepatology approval as the US Food and Drug Administration (FDA) weighs bepirovirsen for
Related to this article
Ochsner Transplant Institute director discusses liver transplant care, robotic kidney transplant, organ preservation, and access gaps.
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
Newly published results from the TRIUMPH-1 study have indicated the direct correlation between the triple agonist and several improvements to weight.
Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.
Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.
Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.
Mirum's antibody led to virologic response and ALT normalization in up to 56% of patients at week 24, vs 0% with delayed treatment.
Advertisement
Advertisement